MDEG-541

Cat. No.:	HY-150259
Molecular Formula:	$C_{35}H_{38}N_4O_6S_2$
Molecular Weight:	674.83
Target:	c-Myc; PROTACs
Pathway:	Apoptosis; PROTAC
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

MDEG-541 is a potent MYC-MAX degrader. MDEG-541 is a PROTAC that based on the MYC-MAX dimerization inhibitor 10058-F4 derivative 28RH and Thalidomide (HY-14658). MDEG-541 shows antiproliferative activity. MDEG-541 decreases the expression of GSPT1, MYC, GSPT2, PLK1 protein[1].

In Vitro

MDEG-541 (10 μM; 3, 12, 24 h) decreases the expression of GSPT1, MYC, GSPT2, PLK1 protein in a time-dependent manner in KP4 cells[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line:	HCT116, PSN1 cells
Concentration:	5, 10, 20 μM
Incubation Time:	24 h
Result:	Decreased the expression of MYC in a dose-dependent manner.

Cell Viability Assay[1]

Cell Line:	HCT116, PSN1 cells
Concentration:	0-50 μM
Incubation Time:	72 h
Result:	Inhibited cell viability with GI_{50}s of 14.3, 10.7 μM for HCT116, PSN1 cells, respectively.

REFERENCES

[1]. Lier S, et al. A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer. Bioorg Chem. 2022 Feb;119:105505.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA